![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
|Videos|August 4, 2021
Integrated Early Phase to Commercial Drug Substance to Drug Product
Author(s)Lonza
In this 15-minute talk, David K. Lyon, PhD, Senior Fellow of Research, Lonza, discusses a flexible, integrated model supporting over 600 small molecule therapies.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Takeda’s Sriman Banerjee Discusses Smart Packaging at CPHI Frankfurt 2025
2
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
3
Standardizing Operations to Meet Global Sustainability and Resilience Goals
4
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One
5
